netFormulary NHS
Birmingham, Sandwell, Solihull and environs APC Formulary
Maintained by Midlands and Lancashire Commissioning Support Unit
 Search
 Formulary Chapter 4: Central nervous system - Full Chapter
04.03.04  Expand sub section  Other antidepressant drugs
Pregabalin
View adult BNF View SPC online View childrens BNF
Second Choice
Green
  • for generalised anxiety disorder
  • ££

Schedule 3 Controlled Drug as of 01/04/2019

 
Link  NHS England: Rescheduling of Gabapentin and Pregabalin as Schedule 3 Controlled Drugs
   
Agomelatine (Valdoxan®)
View adult BNF View SPC online View childrens BNF
Formulary
Amber
 
   
Duloxetine (Cymbalta®)
View adult BNF View SPC online View childrens BNF
Formulary
Amber
 
   
Mirtazapine
View adult BNF View SPC online View childrens BNF
Formulary
Green
  • tablets
  • orodispersible tablets ££ 
  •    
    Venlafaxine tablets
    View adult BNF View SPC online View childrens BNF
    Formulary
    Green
     
       
    Venlafaxine M/R
    View adult BNF View SPC online View childrens BNF
    Formulary
    Green

    APC preferred brands

    • 1st choice: Vensir XL capsules (suggest switching generic prescriptions to this agent)
    • 2nd choice: Venlalic XL tablets
     
       
    Bupropion
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
  • off label use 
  •    
    Tryptophan
    View adult BNF View SPC online View childrens BNF
    Formulary
    Red
     
       
     ....
     Non Formulary Items
    Flupentixol  (Fluanxol®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
     
    Reboxetine  (Edronex®)

    View adult BNF View SPC online View childrens BNF
    Non Formulary
    Black
     
      
    Key
    note Notes
    Section Title Section Title (top level)
    Section Title Section Title (sub level)
    First Choice Item First Choice item
    Non Formulary Item Non Formulary section
    Restricted Drug
    Restricted Drug
    Unlicensed Drug
    Unlicensed
    Track Changes
    Display tracking information
    click to search medicines.org.uk
    Link to adult BNF
    click to search medicines.org.uk
    Link to children's BNF
    click to search medicines.org.uk
    Link to SPCs
    Cytotoxic Drug
    Cytotoxic Drug
    CD
    Controlled Drug
    High Cost Medicine
    High Cost Medicine
    Cancer Drugs Fund
    Cancer Drugs Fund
    NHSE
    NHS England
    Homecare
    Homecare
    CCG
    CCG

    Traffic Light Status Information

    Status Description

    Prescribing in children

    The APC notes that the informed use of unlicensed medicines or of licensed medicines for unlicensed applications (‘off-label’ use) is often necessary in paediatric practice.

    The APC advises GPs to consider specialist prescribing recommendations for Green and Amber medicines that are not subject to ESCAs or RICaDs in combination with the information provided in the BNFC which goes beyond that of marketing authorisations. The BNFC has been designed for rapid reference and the information presented has been carefully selected to aid decisions on prescribing.

      

    Green

    Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications.  

    Amber

    Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate, or initiation and maintenance of prescribing in Primary Care following recommendation from a Specialist.

    Some amber medicines require agreement with the local (internal) medicines committee prior to initiation; others may require a framework to support safe transfer and maintenance of care such as a RICaD or ESCA. The Formulary will be annotated to reflect these requirements.   

    Red

    Medicines for initiation and maintenance prescribing by Specialists only  

    Black

    Non-formulary medicines- medicines not recommended for routine primary care prescribing.  

    Grey

    Positive NICE TA and /or awaiting local clarification on place in therapy ; Please contact your Medicines Optimisation team for more information.  

    netFormulary